Latest News and Press Releases

Pharmazz Inc. announces that Dr. Neil Marwah has joined the Company as its President.

Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin®) as a resuscitative agent

Special Protocol Assessment Agreement Reached Between Pharmazz, Inc. and the U.S. Food and Drug Administration for Phase 3 Clinical Trial of Sovateltide

Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptomsIndia is the first global territory where Tyvalzi™...

The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that...

Centhaquine (Lyfaquin®) is an adrenergic agent that increases cardiac preload by activating alpha2B adrenergic receptors to increase venous blood return to the heart and decreases cardiac afterload by...

Sovateltide produced statistically significant and clinically meaningful improvements in neurological outcomes in acute cerebral ischemic stroke patients and was well tolerated Clinical trial results...

WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in...

WILLOWBROOK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in...